The AJMC® Ophthalmology compendium is a comprehensive resource for clinical news and expert insights for treatment of disorders of the eye.
May 20th 2024
The FDA approved the first 2 biosimilars referencing aflibercept (Eylea). (aflibercept). However, patent litigation has left it unclear when the biosimilars will come to market.
Addressing Unmet Needs and Treatment Gaps in the Clinical Management of Neovascular Age-Related Macular Degeneration: Practical Strategies for Pharmacists in Specialty and Man...
1.5 Credits / Ophthalmology/Optometry
View More
Management of Neuromyelitis Optica Spectrum Disorder: Expert Insights and Updates for Pharmacists, featuring a Patient Perspective
1.5 Credits / Ophthalmology/Optometry
View More
The Promising Role of Novel Targeted Therapies in Addressing Clinical and Economic Burdens in Diabetic Macular Edema
1.5 Credits / Ophthalmology/Optometry
View More
Improving Outcomes and Quality of Care in Age-Related Macular Degeneration and Diabetic Macular Edema: Patient-Centered Strategies in Managed Care
3.0 Credits / Ophthalmology/Optometry
View More
Maximizing Patient Outcomes in Ophthalmologic Diseases: How Managed Care Professionals Play a Key Role in Facilitating Uptake of Biosimilars
1.0 Credit / Ophthalmology/Optometry
View More
Navigating the Advances in the Treatment of Geographic Atrophy: Updates and Strategies for Managed Care
2.0 Credits / Ophthalmology
View More
Anti-VEGF and Gene Therapy Impacting Wet AMD and DME Treatment Landscapes
February 16th 2023Dr Sheth discusses his insights on anti-VEGF therapy that he has noticed in the treatment of wet AMD over the last decade, and Caesar Luo, MD, FASRS, FACS shares his insight on new treatment options and their impact on patient access and cost considerations.
Watch
Dr Michael Cohen Discusses Accessibility of Future Gene Therapies
February 9th 2023Michael N. Cohen, MD, FAAO, retinal surgeon at Wills Eye Hospital in Philadephia and Mid Atlantic Retina, speaks about the future of gene therapy and the accessibility and availability of these therapies moving forward.
Watch
Dr Michael Chiang Speaks About the NEI's Involvement in AMD, Addressing Health Disparities
January 26th 2023Michael Chiang, MD, director of the National Eye Institute, spoke about efforts to address age-related macular degeneration (AMD) as well as health disparities in clinical trials and access to treatment.
Watch
Gene Variants That Protect Against Alzheimer Disease Could Increase Risk of AMD
December 1st 2022The risk of age-related macular degeneration (AMD) could be linked to structural variations in the APOE gene that were previously found to be associated with protection against Alzheimer disease.
Read More
A report from the World Health Organization highlights the global burden of oral diseases; study shows the predictive value of a “good” cholesterol level varies between Black and White patients; CDC report suggests people with impaired vision are not receiving proper health care.
Read More
Dr Michel Michaelides Speaks About Implications of Gene Therapy Study Results in Ophthalmology
October 27th 2022The results of a study showing improved functional vision and retinal sensitivity have implications for gene therapy in ophthalmological conditions, explained Michel Michaelides, MD, FACP, a consultant ophthalmologist and a professor of ophthalmology at the University College London Institute of Ophthalmology's Genetics Department.
Watch
Dr Steven Yeh: Xipere’s New Delivery Method Requires Patient, Physician Education
October 18th 2022Patients with uveitis and their physicians may be very familiar with intravitreal injections, but triamcinolone acetonide injectable suspension (Xipere) has a novel delivery method, said Steven Yeh, MD, professor and the Stanley Truhlsen Jr. Chair in Ophthalmology at the Truhlsen Eye Institute, University of Nebraska Medical Center.
Watch
Dr Parisa Emami-Naeni on the Lack of Racial Diversity in Ophthalmology Residency Programs
October 11th 2022Different factors have contributed to the lack of racial diversity in ophthalmology residency programs, and these programs build the future of the workforce, said Parisa Emami-Naeni, MD, MPH, assistant professor of ophthalmology at University of California, Davis, and vitreoretinal surgeon and uveitis specialist at UC Davis Eye Center.
Watch